Eyegate Pharmaceuticals, Inc.
| NASDAQ: EYEGW | Healthcare / Biotechnology / - |
| 0.0100 | -0.0300 | -75.00% | Vol 5 300 | 1Y Perf -88.89% |
| Jun 24th, 2019 12:41 |
| BID | 0.0100 | ASK | 0.0500 | ||
| Open | 0.0300 | Previous Close | 0.0400 | ||
| Pre-Market | - | After-Trading | - | ||
| - -% | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potencial % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12M | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12M | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12M | -/-/- | Income Ranking | — - | |
| Market Cap (mil) | - | Earnings Rating | Neutral | |
| Price Range Ratio 52wk % | 0.00 | Earnings Date | - |
Today's Price Range 0.01000.0300 | 52wk Range 0.01000.1700 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Month | -50.00% | ||
| 3 Months | -50.00% | ||
| 6 Months | -50.00% | ||
| 1 Year | -88.89% | ||
| 3 Years | -98.51% | ||
| 5 Years | - |
| Management Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | - | |||
ROE last 12 Months | - | |||
Return on Assets (5Y Avg) | - | |||
ROA last 12 Months | - | |||
Return on Capital (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | - | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | - | |||
PS Ratio | - | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | - | |||
Cash Flow Per Share | - | |||
Price to Tangible Book | - | |||
Book Value per Share | - | |||
Enterprise Value (in ths.) | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | - | |||
Current Ratio | - | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | - | |||
Interest Coverage | - | |||
| Leverage Ratio | - |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | - | |||
EBIT Margin | - | |||
EBITDA Margin | - | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (in ths.) | - | |||
Revenue per Share | - | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 5 300 |
| Shares Outstanding (in ths.) | 0 |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 11 139 |
| Avg. Weekly Volume | 3 800 |
| Avg. Monthly Volume | 8 795 |
| Avg. Quarterly Volume | 12 172 |
